Novartis says Alcon glaucoma treatment approved in EU




Whatsapp News

Novartis says Alcon glaucoma treatment approved in EUZURICH – Swiss pharmaceutical group Novartis said the Commission has approved its eyecare unit Alcon’s Simbrinza for glaucoma, a chronic, sight-threatening eye disease.

Alcon said a statement Monday the Simbrinza eye drops suspension had been approved to decrease elevated intraocular adult patients open-angle glaucoma or ocular hypertension.[eap_ad_2]

“We are pleased to introduce the only fixed combination therapy without a beta-blocker to help glaucoma patients manage progressive eye condition,” Jeff George, global head of Alcon, said the statement. (Reuters)[eap_ad_3]